Literature DB >> 28575166

LTA4H regulates cell cycle and skin carcinogenesis.

Naomi Oi1, Hiroyuki Yamamoto1, Alyssa Langfald1, Ruihua Bai1, Mee-Hyun Lee1, Ann M Bode1, Zigang Dong1.   

Abstract

Leukotriene A4 hydrolase (LTA4H), a bifunctional zinc metallo-enzyme, is reportedly overexpressed in several human cancers. Our group has focused on LTA4H as a potential target for cancer prevention and/or therapy. In the present study, we report that LTA4H is a key regulator of cell cycle at the G0/G1 phase acting by negatively regulating p27 expression in skin cancer. We found that LTA4H is overexpressed in human skin cancer tissue. Knocking out LTA4H significantly reduced skin cancer development in the 7,12-dimethylbenz(a)anthracene (DMBA)-initiated/12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted two-stage skin cancer mouse model. LTA4H depletion dramatically decreased anchorage-dependent and -independent skin cancer cell growth by inducing cell cycle arrest at the G0/G1 phase. Moreover, our findings showed that depletion of LTA4H enhanced p27 protein stability, which was associated with decreased phosphorylation of CDK2 at Thr160 and inhibition of the CDK2/cyclin E complex, resulting in down-regulated p27 ubiquitination. These findings indicate that LTA4H is critical for skin carcinogenesis and is an important mediator of cell cycle and the data begin to clarify the mechanisms of LTA4H's role in cancer development.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28575166      PMCID: PMC6248358          DOI: 10.1093/carcin/bgx049

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  43 in total

1.  Role of LTB₄ in the pathogenesis of elastase-induced murine pulmonary emphysema.

Authors:  Y Michael Shim; Mikell Paige; Halim Hanna; Su H Kim; Marie D Burdick; Robert M Strieter
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-09-03       Impact factor: 5.464

2.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

3.  The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency.

Authors:  Robert A Stockley; Darren L Bayley; Ipek Unsal; Lee J Dowson
Journal:  Am J Respir Crit Care Med       Date:  2002-06-01       Impact factor: 21.405

4.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

5.  Crystal structures of leukotriene A4 hydrolase in complex with captopril and two competitive tight-binding inhibitors.

Authors:  Marjolein M G M Thunnissen; Björn Andersson; Bengt Samuelsson; Chi-Huey Wong; Jesper Z Haeggström
Journal:  FASEB J       Date:  2002-08-07       Impact factor: 5.191

6.  Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin.

Authors:  Xiaoxin Chen; Ning Li; Su Wang; Nan Wu; Jungil Hong; Xiaolong Jiao; Mark J Krasna; David G Beer; Chung S Yang
Journal:  J Natl Cancer Inst       Date:  2003-07-16       Impact factor: 13.506

Review 7.  Leukotriene A4 hydrolase as a target for cancer prevention and therapy.

Authors:  X Chen; S Wang; N Wu; C S Yang
Journal:  Curr Cancer Drug Targets       Date:  2004-05       Impact factor: 3.428

8.  CXCR2-specific chemokines mediate leukotriene B4-dependent recruitment of neutrophils to inflamed joints in mice with antigen-induced arthritis.

Authors:  Renata Grespan; Sandra Y Fukada; Henrique P Lemos; Silvio M Vieira; Marcelo H Napimoga; Mauro M Teixeira; Alasdair R Fraser; Foo Y Liew; Iain B McInnes; Fernando Q Cunha
Journal:  Arthritis Rheum       Date:  2008-07

Review 9.  Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer.

Authors:  Dan D Hershko
Journal:  Cancer       Date:  2008-04-01       Impact factor: 6.860

10.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.

Authors:  M Pagano; S W Tam; A M Theodoras; P Beer-Romero; G Del Sal; V Chau; P R Yew; G F Draetta; M Rolfe
Journal:  Science       Date:  1995-08-04       Impact factor: 47.728

View more
  6 in total

1.  Identification of Human Leukotriene A4 Hydrolase Inhibitors Using Structure-Based Pharmacophore Modeling and Molecular Docking.

Authors:  Suaad A Audat; Nizar A Al-Shar'i; Buthina A Al-Oudat; Amanda Bryant-Friedrich; Mel F Bedi; Aref L Zayed; Qosay A Al-Balas
Journal:  Molecules       Date:  2020-06-22       Impact factor: 4.411

2.  Inhibition of LTA4H by bestatin in human and mouse colorectal cancer.

Authors:  Simin Zhao; Ke Yao; Dan Li; Kangdong Liu; Guoguo Jin; Mingyang Yan; Qiong Wu; Hanyong Chen; Seung Ho Shin; Ruihua Bai; Gangcheng Wang; Ann M Bode; Ziming Dong; Zhiping Guo; Zigang Dong
Journal:  EBioMedicine       Date:  2019-05-10       Impact factor: 8.143

Review 3.  Medicinal chemistry inspired by ginger: exploring the chemical space around 6-gingerol.

Authors:  Sara Hassan Hassan Ahmed; Tímea Gonda; Attila Hunyadi
Journal:  RSC Adv       Date:  2021-08-04       Impact factor: 4.036

Review 4.  Current knowledge of the implication of lipid mediators in psoriasis.

Authors:  Mélissa Simard; Sophie Morin; Zainab Ridha; Roxane Pouliot
Journal:  Front Immunol       Date:  2022-08-26       Impact factor: 8.786

5.  Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer.

Authors:  Carolina Moretto Carnielli; Carolina Carneiro Soares Macedo; Tatiane De Rossi; Daniela Campos Granato; César Rivera; Romênia Ramos Domingues; Bianca Alves Pauletti; Sami Yokoo; Henry Heberle; Ariane Fidelis Busso-Lopes; Nilva Karla Cervigne; Iris Sawazaki-Calone; Gabriela Vaz Meirelles; Fábio Albuquerque Marchi; Guilherme Pimentel Telles; Rosane Minghim; Ana Carolina Prado Ribeiro; Thaís Bianca Brandão; Gilberto de Castro; Wilfredo Alejandro González-Arriagada; Alexandre Gomes; Fabio Penteado; Alan Roger Santos-Silva; Márcio Ajudarte Lopes; Priscila Campioni Rodrigues; Elias Sundquist; Tuula Salo; Sabrina Daniela da Silva; Moulay A Alaoui-Jamali; Edgard Graner; Jay W Fox; Ricardo Della Coletta; Adriana Franco Paes Leme
Journal:  Nat Commun       Date:  2018-09-05       Impact factor: 14.919

Review 6.  Current Status of the Use of Multifunctional Enzymes as Anti-Cancer Drug Targets.

Authors:  Carla S S Teixeira; Sérgio F Sousa
Journal:  Pharmaceutics       Date:  2021-12-21       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.